tiprankstipranks
Trending News
More News >
LENZ Therapeutics Positioned for Success with LNZ100 Ahead of 2025 PDUFA Date
PremiumRatingsLENZ Therapeutics Positioned for Success with LNZ100 Ahead of 2025 PDUFA Date
2M ago
Positive Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strategic Positioning
Premium
Ratings
Positive Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strategic Positioning
2M ago
Strong Buy Recommendation for LENZ Therapeutics: LNZ100 Poised to Disrupt Presbyopia Market with Best-in-Class Efficacy and Safety
Premium
Ratings
Strong Buy Recommendation for LENZ Therapeutics: LNZ100 Poised to Disrupt Presbyopia Market with Best-in-Class Efficacy and Safety
2M ago
Lenz Therapeutics files to sell 13.07M shares of common stock for holders
PremiumThe FlyLenz Therapeutics files to sell 13.07M shares of common stock for holders
3M ago
Lenz Therapeutics files $500M mixed securities shelf
Premium
The Fly
Lenz Therapeutics files $500M mixed securities shelf
3M ago
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook
Premium
Company Announcements
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook
4M ago
Lenz Therapeutics price target raised to $47 from $44 at Citi
PremiumThe FlyLenz Therapeutics price target raised to $47 from $44 at Citi
4M ago
Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid FDA Progress and Commercial Readiness
Premium
Ratings
Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid FDA Progress and Commercial Readiness
4M ago
Buy Rating for LENZ Therapeutics Driven by Promising LNZ100 Eye Drop Prospects
Premium
Ratings
Buy Rating for LENZ Therapeutics Driven by Promising LNZ100 Eye Drop Prospects
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100